FDA To Review Abbott's XIENCE Drug Eluting Heart Stent

Armen Hareyan's picture
Advertisement

Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE V Drug Eluting Heart Stent to FDA Advisory Committee on November 29

Advertisement

Data in Pre-Market Approval Application Are First Ever to Demonstrate Superiority of One Drug Eluting Stent Over Another in a Randomized Controlled Clinical Trial

New Data Released Confirms Consistency of Results for Late Loss, TVF, MACE, TLR, Cardiac Death, MI, Thrombosis Across all XIENCE V Studies

Abbott today released a summary of clinical highlights on the XIENCE

Advertisement